We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Multiparametric MRI-based VI-RADS: can it predict 1- to 5-year recurrence of bladder cancer?
- Authors
Xu, Xiaopan; Huang, Yiping; Liu, Yang; Cai, Qian; Guo, Yan; Wang, Huanjun; Lu, Hongbing
- Abstract
Objectives: To evaluate whether Vesical Imaging-Reporting And Data System (VI-RADS) scores based on multiparametric MRI (mp-MRI) can predict bladder cancer (BCa) recurrence. Methods: In this retrospective study, 284 patients with pathologically confirmed bladder neoplasms from November 2011 to October 2020 were included. Two radiologists blindly and independently scored mp-MRI scans according to VI-RADS. Scoring inconsistency was resolved in consensus. The latest follow-up was completed in December 2022. Pearson's correlation analyses, independent-sample t-tests, and receiver operating characteristic analyses were performed to assess the efficacy of VI-RADS score for the 1- to 5-year recurrence prognostication. Results: Based on the latest follow-up, 37 (of 284, 13.0%), 69 (of 284, 24.3%), 70 (of 234, 29.9%), 72 (of 190, 37.9%), and 63 (of 135, 46.7%) patients had cancer recurrence at 1- to 5-year follow-up, respectively. VI-RADS scores showed significantly intergroup differences between recurrent and nonrecurrent cases during 1- to 4-year surveillance (p < 0.05). The recurrence-free survival was significantly higher in patients with VI-RADS scores of 1 or 2, compared to those with scores of 3, 4, or 5 (p < 0.05). Areas under the receiver operating characteristic curves for 1- to 5-year recurrence prediction were 0.744, 0.686, 0.656, 0.595, and 0.536, respectively. VI-RADS score of 3 or more was the threshold for 1-year recurrence assessment, and VI-RADS more than 3 was the cutoff for 2-year recurrence prediction. Conclusion: VI-RADS score has potential in preoperative prognostication of BCa recurrence, but its predictive power decreases over time. Clinical relevance statement: VI-RADS has potential in bladder cancer recurrence assessment, but its prognostic value decreases over time. Patients with VI-RADS ≥ 3 may be more likely to recur in 1 or 2 years postoperatively, thus should be performed with intensive surveillances. Key Points: • VI-RADS scores had significant differences in 1- to 4-year recurrent and nonrecurrent patient groups. • Patients with VI-RADS scores of ≤ 2 showed more favorable recurrence-free survival outcomes. • The prognostic value of VI-RADS score decreased over time for bladder cancer recurrence prediction.
- Subjects
CANCER relapse; BLADDER cancer; PEARSON correlation (Statistics); RECEIVER operating characteristic curves; SURVIVAL rate
- Publication
European Radiology, 2024, Vol 34, Issue 5, p3034
- ISSN
0938-7994
- Publication type
Article
- DOI
10.1007/s00330-023-10387-8